Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litx (Talaporfin Sodium) for Inoperable HCC
NCT00122876Phase 2Completed
- Sponsor
- Light Science Oncology
- Start
- Apr 2005
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of talaporfin sodium in hepatocellular carcinoma (HCC), sponsored by Light Science Oncology. Primary endpoint: Safety. Started Apr 2005; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00122876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122876.